Clinical Trial Details

Intrepid (INTermediate Risk Erection Preservation Trial:) A Randomized Phase II Trial of Radiation Therapy and Darolutamide for Prostate Cancer - (DF/HCC 19-202)

This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, this research would help determine whether this new form of hormonal therapy is as effective as the standard hormone therapy while also preserving erectile function.

DF/HCC 19-202

Learn More

Principal Investigator(s)

Anthony Gulati, MD


Dana-Farber Cancer Institute


Ed Hatton, RN at 203-358-8879 or [email protected]


Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.